Please login or register to print this page.

ARTICLE CONTRIBUTORS

European Society of Cardiology

Clinical Articles, News & Views

Management of AF still suboptimal in Europe

Statistics show that while oral anticoagulant use for atrial fibrillation (AF) treatment has increased, new oral anticoagulant (NOAC) use is still low, while compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal, according to research1 published recently in Europace.

For the pilot phase, nine European countries participated, with enrollment starting in February 2012 and ending in March 2013. 3,119 patients with AF were enrolled, with full data on clinical subtype available for 3,049 patients (40.4% female; mean age 68.8 years). Common co-morbidities were hypertension, coronary disease and heart failure. Lone AF was present in only 3.9% (122 patients). Asymptomatic AF was common, particularly among those with permanent AF.

Corresponding author and Chairman of the EuroObservational Research Programme-Atrial Fibrillation (EORP-AF) programme, Professor Gregory Lip (Birmingham, UK) said: “New guidelines on the management of AF were recently published by the ESC2 and we wanted to find out how clinicians were adhering to them. Our registry was a survey of their implementation as well as the uptake of catheter ablation, new antithrombotic drugs and new anti arrhythmic agents, amongst other data.”

Professor Lip added: “Drug prescription patterns showed interesting changes over the last decade. Adherence to recommendations for OAC use has improved somewhat (in 80% overall), although they are significantly less used in females. NOACs, on the contrary, were used only in 8.4%, but reflected the fact that NOACs were not widely available in all countries.”

Professor Aldo Maggioni (EORP Scientific Coordinator, Sophia Antipolis, France) said: “This registry allowed a timely assessment of the clinical scenario in Europe regarding the management of AF. The follow up period of the survey will allow the evaluation of morbidity/mortality over time and also the comparison between outcomes in European regions with different patterns of practice and the dissimilar adherence to ESC guidelines.”

“The pilot registry allowed us to measure current disease management strategies. We look forward to a more comprehensive assessment of the management and treatment of AF in all ESC member countries once we have the results of the EORP-AF general long-term registry. We have high hopes to be in a position to announce results from 2015 onwards,” concluded Professor Lip.

References

1. Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EuroObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2013. http://dx.doi.org/10.1093/europace/eut373

2. ESC Clinical Practice Guidelines. Atrial Fibrillation (Management of) 2010 and Focused Update (2012). Available in full from: http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/atrial-fibrillation.aspx

Published on: December 20, 2013

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.